Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

[1]  M. Fabrini,et al.  A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma , 2009, Journal of Neuro-Oncology.

[2]  F. Ammannati,et al.  Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience , 2008, Anti-cancer drugs.

[3]  W. Mason,et al.  The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma , 2008 .

[4]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Reifenberger,et al.  Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Brandes,et al.  Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) , 2006, British Journal of Cancer.

[7]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[8]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[9]  A. Brandes,et al.  Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy , 2004, Cancer.

[10]  A. Brandes,et al.  How effective is BCNU in recurrent glioblastoma in the modern era? , 2004, Neurology.

[11]  Y. Cihan,et al.  Post-Operative Sequential Chemo-Radiotherapy in High-Grade Cerebral Gliomas with Fotemustine , 2004, Journal of chemotherapy.

[12]  Luca Regli,et al.  Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.

[13]  M. Weichenthal,et al.  Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R Alexandra Goldbohm,et al.  Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. , 2003, Cancer research.

[15]  A. Hauschild,et al.  A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma , 2003, Melanoma research.

[16]  A. Brandes,et al.  New strategy developments in brain tumor therapy. , 2001, Current pharmaceutical design.

[17]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[18]  J. Herman,et al.  Predicting lung cancer by detecting aberrant promoter methylation in sputum. , 2000, Cancer research.

[19]  M. Ducreux,et al.  A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. , 2000, European journal of cancer.

[20]  E. Raymond,et al.  Logistic regression model of fotemustine toxicity combining independent phase II studies , 1996, Cancer.

[21]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Glabbeke,et al.  Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC‐Melanoma Cooperative Group (MCG) , 1995, Melanoma research.

[23]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. D’Incalci,et al.  Antitumor activity of the novel nitrosourea S10036 in rodent tumors. , 1988, Anticancer research.

[25]  C. Jacquillat,et al.  Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule. , 1987, Cancer research.

[26]  V A Levin,et al.  Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. , 1980, Journal of medicinal chemistry.

[27]  J. Uhm.  Temozolomide Rechallenge in Recurrent Malignant Glioma by Using a Continuous Temozolomide Schedule: The “Rescue” Approach , 2009 .

[28]  G. Milano,et al.  In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea , 2004, Cancer Chemotherapy and Pharmacology.

[29]  K. Schallreuter,et al.  Positive phase II study in the treatment of advanced malignant melanoma with fotemustine , 2004, Cancer Chemotherapy and Pharmacology.

[30]  D. Henzel,et al.  Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human and rat brain biopsies. , 1991, Chemotherapy.